Table 2.

Anti-tetanus-toxoid antibody concentrations

GroupaTotal IgGIgG1Geometric mean (range) concn (μg/ml) on the indicated day:Geometric mean (range) IgA concn (AU/ml) on the following day:
IgG2IgG3IgG4
Geometric mean (range) concn (μg/ml) on the following day:FIbGeometric mean (range) concn (μg/ml) on the following day:FIDayDayDay
030030030030030030
I4.4 (1.1–15.4)7.7c (2.7–21.9)2.0 (0.8–6.1)3.7 (1.1–12.2)6.6c (2.0–18.6)2.1 (0.7–6.0)0.2 (0.1–1.0)0.4d (0.1–1.5)0.4 (0.2–1.0)0.5d (0.2–1.2)0.1 (0.01–0.7)0.2 (0.05–1.1)3.9 (1.6–13.4)5.8 (2.2–20.1)
II6.5 (1.3–22.7)29.4 (12.7–62.9)9.4 (1.6–48.0)5.3 (1.1–20.4)25.5 (11.1–57.3)9.2 (1.8–41.0)0.4 (0.05–3.5)1.3 (0.4–7.0)0.6 (0.1–1.5)1.6 (0.7–4.9)0.2 (0.05–4.7)0.6 (0.05–8.2)4.0 (1.3–17.2)8.3 (4.6–13.3)
Control4.9 (1.0–22.6)40.1 (23.1–82.6)18.9 (1.3–55.1)5.8 (1.5–26.7)46.9 (28.3–92.3)19 (1.3–61.5)0.2 (0.1–0.3)0.7 (0.3–2.9)0.4 (0.1–1.6)0.9 (0.7–1.5)0.1 (0.05–0.1)0.3 (0.2–1.1)2.9 (1.1–8.8)14.3 (8.0–25.8)
  • a HIV-infected individuals with a CD4+ T-lymphocyte counts of <200 × 106/liter (group I; n = 13) and ≥200 × 106/liter (group II; n = 11) and healthy controls (group C; n = 5).

  • b FI, fold increase in concentration is expressed as the ratio of the postvaccination concentration to the prevaccination concentration.

  • c P < 0.05 compared with group II and controls.

  • d P < 0.05 compared with group II.